Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 DeficiencyGlobeNewsWire • 04/08/24
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/05/24
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/24
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024GlobeNewsWire • 03/26/24
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/12/24
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/26/24
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/07/23
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 10/10/23
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare ConditionsGlobeNewsWire • 10/10/23
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual MeetingGlobeNewsWire • 10/06/23
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZYPRNewsWire • 08/18/23
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/08/23
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 DeficiencyGlobeNewsWire • 07/26/23
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701GlobeNewsWire • 06/27/23